ConductScience.org, home

Comparison · NCT03154333-eae01485

Diacerein 1% Ointment vs Vehicle Ointment: Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Diacerein 1% Ointment vs Vehicle Ointment: Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area. Trial comparisons, record NCT03154333-eae01485. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03154333-eae01485

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5710.3910.735wilson
Risk in group 20.5380.3550.712wilson
Risk difference, group 1 minus group 20.033-0.2180.279newcombe hybrid score
Risk ratio, group 1 over group 21.060.6571.71log
Odds ratio, group 1 over group 21.140.393.35log
Number needed to treat, for one more participant with the outcome on Diacerein 1% Ointment than on Vehicle Ointment30.3from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Diacerein 1% Ointmentdiacerein 1% ointment will be used for 8 weeks~diacerein 1% ointment: diacerein 1% ointment administered topically1628OG000
Group 2Vehicle Ointmentvehicle ointment will be used for 8 weeks~vehicle ointment administered topically1426OG001

Outcome

Type
PRIMARY
Title
Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area
Description
Analysis of the proportion of subjects who achieved a ≥60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8
Time frame
Baseline to Week 8
Population
All efficacy analyses were conducted using the Intent to Treat (ITT) Population that consisted of all randomized subjects who were dispensed study drug. Subjects were included in the treatment group to which they were assigned.

Source ClinicalTrials.gov

Trial

Title
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
NCT number
NCT03154333
Phases
PHASE2
Conditions
Epidermolysis Bullosa Simplex
Interventions
diacerein 1% ointment, A placebo ointment
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Results first posted
2019-11-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03154333-eae01485